Cyxone Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Kjell Stenberg

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	no data
Board average tenure	less than a year

Recent management updates

Recent updates

CEO

Kjell Stenberg (71 yo)

less than a year

Tenure

Dr. Kjell G. Stenberg, Ph D., is one of the Co-Founders and has been the Chief Executive Officer of Cyxone AB (publ) since April 22, 2024. He previously served as Chief Executive Officer of Cyxone AB (publ...

Board Members

Name	Position	Tenure	Compensation	Ownership
Bert Junno	Director	no data	kr875.00k	1.01% SEK 16.7k
Christian Gruber	Chairman of the Scientific Advisory Board	no data	no data	no data
Maarten Kraan	Senior Scientific Advisor	3.8yrs	no data	no data
Rikard Holmdahl	Senior Scientific Advisor	less than a year	no data	no data
Michael Oredsson	Chairman	less than a year	no data	no data
Andrew Scorey	Director	less than a year	no data	no data
Jurgen Reess	Director	less than a year	no data	no data

1.0yrs

Average Tenure

61yo

Average Age

Experienced Board: 4CX's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.

Cyxone Management

Management criteria checks 0/4

Key information

Recent management updates

Cyxone AB (publ) Announces Chief Executive Officer Changes

Cyxone Announces CFO Changes

Cyxone AB (publ) Announces Board Changes

Cyxone AB (Publ) Appoints Carl-Magnus Högerkorp as Permanent CEO

Cyxone AB (Publ) Announces That the Members of the Nomination Committee for Annual General Meeting 2023

Cyxone Appoints Erika Samuelsson as Chief Development Officer

Recent updates

Cyxone AB (publ) Announces Chief Executive Officer Changes

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

New major risk - Financial position

Cyxone AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024

Cyxone AB (publ) to Report Q4, 2024 Results on Feb 25, 2025

New major risk - Revenue and earnings growth

Cyxone AB (publ) to Report Q3, 2023 Results on Nov 21, 2023

Cyxone Announces CFO Changes

Cyxone AB (publ) Announces Board Changes

Cyxone AB (Publ) Receives Ethical and Regulatory Approval from Georgia to Conduct Clinical Phase 2B Study in RA

Cyxone AB (Publ) Advances the Patent Portfolio for Rabeximod

Cyxone AB (publ) to Report Fiscal Year 2023 Results on Feb 23, 2024

Cyxone AB (Publ) Appoints Carl-Magnus Högerkorp as Permanent CEO

Cyxone (publ) Receives Ethical and Regulatory Approval from Hungary to Start Clinical Phase 2b Study in RA

Cyxone AB (Publ) Announces That the Members of the Nomination Committee for Annual General Meeting 2023

Cyxone Appoints Erika Samuelsson as Chief Development Officer

Cyxone AB (publ) Receives Regulatory Approval to Start Clinical Phase 2B Study in RA

Cyxone AB (Publ) Appoints Erika Samuelsson as Chief Development Officer

Cyxone AB (Publ) Announces CFO Changes

Cyxone AB (publ) to Report Q3, 2022 Results on Oct 27, 2023

Cyxone Files Submission to Start Clinical Phase 2B Study in Poland and Georgia

Cyxone Receives Pre-IND Response from the US FDA regarding RA study

Cyxone (Publ) Files Regulatory Submission to Start Clinical Phase 2B Study with Rabeximod

Cyxone Announces Executive Changes

Cyxone AB Announces Promising T20k/Kora Combination Therapy Efficacy in Preclinical Therapeutic Model of MS

Safety Confirmation and Observed Trends in Covid-19 Study Build Further Confidence in Cyxone's Rheumatoid Arthritis Program

Cyxone (publ) Announces Resignation of Cornel Pater as Chief Medical Officer

Cyxone (publ) Reports Publication of Four Patent Applications Pertaining to its Drug Candidate Rabeximod

Cyxone (publ) Initiates Early Operations with Global Contract Research Organization to Conduct Phase 2B Trial in Rheumatoid Arthritis

Cyxone Files Patent Application with Potential to Extend Market Exclusivity of the Drug Candidate Rabeximod

Cyxone AB (Publ) Comments on the Covid-19 Study Results

Cyxone (Publ) Presents Top-Line Results from A Phase 2 Study of Rabeximod in Covid-19 Patients

Cyxone AB (Publ) Expects to Communicate Top-Line Results from A Recently Concluded Phase 2 Trial of Its Drug Candidate Rabeximod in Covid-19 Patients

CFO & Interim CEO Ola Skanung has left the company

Cyxone Announces Rabeximod in Covid-19 Phase 2 Trial Closed and Data to Be Reports in Third Quarter

Cyxone Explores Expanding into New Regions to Mitigate Potential Delay in Covid-19 Trial Completion

Chief Operating Officer has left the company

Cyxone Joins Forces with Leading Rheumatoid Arthritis Expert

Cyxone Initiates Feasibility Preclinical Studies to Optimize Path Forward for Multiple Sclerosis Drug Candidate T20K

Cyxone AB (publ) to Report Q4, 2021 Results on Feb 11, 2022

Cyxone (publ.) Reports First Covid-19 Patient Screened in Phase 2 Clinical Trial of Rabeximod

Cyxone AB (publ), Annual General Meeting, Jun 03, 2021

Cyxone AB (publ) Files an IND in the US with Rabeximod Following Positive Feed-Back from Pre-IND Meeting with the FDA

New 90-day low: €0.48

Cyxone AB (publ) Files Patent Application to Extend Exclusivity of Rabeximod

New 90-day low: €0.49

Cyxone Announces Expanded Plans for Rabeximod

New 90-day low: €0.50

Cyxone AB (Publ) Revises the Development Plan for Rabeximod

New 90-day high - €0.71

CEO

Tenure

Board Members

Average Tenure

Average Age